Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Amisulpride for PONV in Gynecological Surgery
NCT06887621Phase 2Active, not recruiting
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Apr 2025
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in postoperative nausea and vomiting (PONV) comparing Placebo with Oral Amisulpride (2 arms). Primary endpoint: Number of participants with complete response to PONV at 24 hours. Started Apr 2025; status: active, not recruiting.
02
Drugs
amisulpride
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT06887621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06887621.